Beta-defensin 133 (DEFB133)

Beta-defensin 133 (DEFB133) is a member of the beta-defensin family—a group of small, cationic, and disulfide-rich antimicrobial peptides that play a pivotal role in the innate immune response in mammals[1][2]. Beta-defensins, including DEFB133, exhibit broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses, primarily through membrane disruption facilitated by their characteristic structure composed of three beta-strands stabilized by three intramolecular disulfide bonds[1][2]. DEFB133 has predicted chemokine-like functions, including chemoattractant activity for immune cells, and is capable of binding the chemokine receptor CCR6[3][4]. The defensins' structural resilience, conferred by disulfide bonds, allows them to maintain antimicrobial functions despite sequence diversity[1][2]. The precise tissue distribution and pathological associations for DEFB133 remain under investigation, with some datasets linking it to immune activity and possible expression changes in inflammatory or infectious states[3]. If you have a specific therapeutic targeting or disease context for DEFB133, please indicate; currently, it is not considered a standard drug target.

Other names

Beta-defensin 133Defensin, beta 133DEFB133Defensin beta 133DB133_HUMANDefb133

Not applicable (no known therapeutic agents target DEFB133 directly)